Stock Track | HUA MEDICINE-B Soars 5.02% Following Strong H1 2025 Results and Promising Outlook

Stock Track

Aug 29

HUA MEDICINE-B (02552), an innovative pharmaceutical company focused on diabetes treatment, saw its stock price soar by 5.02% in Friday's trading session. This surge comes on the heels of the company's impressive interim results for the first half of 2025, which showcase significant financial and operational improvements.

The company reported a remarkable 112% year-on-year increase in total revenue, reaching approximately RMB 217.4 million. HUA MEDICINE-B achieved its first semi-annual profitability, with a pre-tax profit of RMB 1.1839 billion, largely due to the recognition of deferred revenue from the termination of an agreement with Bayer. The company's flagship product, HTOLYSE®, demonstrated strong market performance with sales volume increasing by 108% year-on-year to 1.764 million boxes.

Investors appear optimistic about HUA MEDICINE-B's future prospects, including its expanding R&D pipeline for combination therapies, progress in international markets, and the development of second-generation GKA. The company's strategic focus on "diabetes and metabolic diseases" and its efforts to optimize cost structure have positioned it well for continued growth in the competitive biomedical sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1133011095"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1133011095\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1133011095?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-29 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133011095","market":"us","top_or_hot":-1,"title":"Stock Track | HUA MEDICINE-B Soars 5.02% Following Strong H1 2025 Results and Promising Outlook","media":"Stock Track","content":"<p>HUA MEDICINE-B (02552), an innovative pharmaceutical company focused on diabetes treatment, saw its stock price soar by 5.02% in Friday's trading session. This surge comes on the heels of the company's impressive interim results for the first half of 2025, which showcase significant financial and operational improvements.</p>\n\n<p>The company reported a remarkable 112% year-on-year increase in total revenue, reaching approximately RMB 217.4 million. HUA MEDICINE-B achieved its first semi-annual profitability, with a pre-tax profit of RMB 1.1839 billion, largely due to the recognition of deferred revenue from the termination of an agreement with Bayer. The company's flagship product, HTOLYSE®, demonstrated strong market performance with sales volume increasing by 108% year-on-year to 1.764 million boxes.</p>\n\n<p>Investors appear optimistic about HUA MEDICINE-B's future prospects, including its expanding R&D pipeline for combination therapies, progress in international markets, and the development of second-generation GKA. The company's strategic focus on \"diabetes and metabolic diseases\" and its efforts to optimize cost structure have positioned it well for continued growth in the competitive biomedical sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | HUA MEDICINE-B Soars 5.02% Following Strong H1 2025 Results and Promising Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | HUA MEDICINE-B Soars 5.02% Following Strong H1 2025 Results and Promising Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-29 09:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HUA MEDICINE-B (02552), an innovative pharmaceutical company focused on diabetes treatment, saw its stock price soar by 5.02% in Friday's trading session. This surge comes on the heels of the company's impressive interim results for the first half of 2025, which showcase significant financial and operational improvements.</p>\n\n<p>The company reported a remarkable 112% year-on-year increase in total revenue, reaching approximately RMB 217.4 million. HUA MEDICINE-B achieved its first semi-annual profitability, with a pre-tax profit of RMB 1.1839 billion, largely due to the recognition of deferred revenue from the termination of an agreement with Bayer. The company's flagship product, HTOLYSE®, demonstrated strong market performance with sales volume increasing by 108% year-on-year to 1.764 million boxes.</p>\n\n<p>Investors appear optimistic about HUA MEDICINE-B's future prospects, including its expanding R&D pipeline for combination therapies, progress in international markets, and the development of second-generation GKA. The company's strategic focus on \"diabetes and metabolic diseases\" and its efforts to optimize cost structure have positioned it well for continued growth in the competitive biomedical sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02552","symbol_name":"华领医药-B","start_time":0,"source_url":"","article_id":"1133011095","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133011095","pubTimestamp":1756431643,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"HUA MEDICINE-B (02552), an innovative pharmaceutical company focused on diabetes treatment, saw its stock price soar by 5.02% in Friday's trading session. This surge comes on the heels of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02552":"华领医药-B"},"translate_title":"个股赛道|2025年上半年业绩强劲，前景看好，华领医药-B飙升5.02%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02552":1},"content_text":"HUA MEDICINE-B (02552), an innovative pharmaceutical company focused on diabetes treatment, saw its stock price soar by 5.02% in Friday's trading session. This surge comes on the heels of the company's impressive interim results for the first half of 2025, which showcase significant financial and operational improvements.\nThe company reported a remarkable 112% year-on-year increase in total revenue, reaching approximately RMB 217.4 million. HUA MEDICINE-B achieved its first semi-annual profitability, with a pre-tax profit of RMB 1.1839 billion, largely due to the recognition of deferred revenue from the termination of an agreement with Bayer. The company's flagship product, HTOLYSE®, demonstrated strong market performance with sales volume increasing by 108% year-on-year to 1.764 million boxes.\nInvestors appear optimistic about HUA MEDICINE-B's future prospects, including its expanding R&D pipeline for combination therapies, progress in international markets, and the development of second-generation GKA. The company's strategic focus on \"diabetes and metabolic diseases\" and its efforts to optimize cost structure have positioned it well for continued growth in the competitive biomedical sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}